Riociguat, the inaugural sGC stimulator approved for clinical use [5], has seen restricted application in HF treatment due to its brief half-life, a consequence of metabolism by cytochrome P450 (CYP) enzymes [6]. Here, SGCB is linked to hydrops fetalis.